查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
干细胞治疗的市场规模，占有率，趋势分析:各类型，各细胞来源，各治疗用途，各地区展望，各竞争策略，至2030年的各市场区隔预测
市场调查报告书
商品编码
1089967

干细胞治疗的市场规模，占有率，趋势分析:各类型，各细胞来源，各治疗用途，各地区展望，各竞争策略，至2030年的各市场区隔预测

Stem Cell Therapy Market Size, Share & Trends Analysis By Type, By Cell source, By Therapeutic Application, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 271 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球干细胞治疗的市场规模，预计今后以15.8％的年复合成长率扩大，至2030年达到7亿19万美元。干细胞研究增加，干细胞製造的GMP检定设施，诱导性多功能干细胞的需求高涨等成为市场促进因素。

本报告提供全球干细胞治疗市场相关调查，市场概要，以及各类型，细胞来源，各治疗用途，各地区的趋势，及加入此市场的主要企业的简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长要素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 课题
  • COVID-19干细胞治疗市场的影响

第5章 市场变数及预测

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 热图分析

第6章 全球干细胞治疗市场，各类型，2019年～2030年(100万美元)

  • 同类干细胞治疗
  • 自体干细胞治疗

第7章 全球干细胞治疗市场，各细胞来源，2019年～2030年(100万美元)

  • 脂肪组织来源
  • 骨髓来源
  • 胎盘/脐带来源
  • 其他

第8章 全球干细胞治疗市场，各治疗用途，2019年～2030年(100万美元)

  • 心血管疾病
  • 发炎性疾病及自体免疫疾病
  • 肌肉骨骼系统障碍
  • 神经病变
  • 其他
  • 手术
  • 创伤、损伤

第9章 全球干细胞治疗市场，各地区，2019年～2030年(100万美元)

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲

第10章 企业简介

  • AlloSource
  • Anterogen
  • BioRestorative Therapies
  • BrainStorm Cell Therapeutics
  • Cellular Biomedicine Group
  • CORESTEM
  • Holostem Terapie Avanzate Srl
  • Hope Biosciences
  • JCR Pharmaceuticals
  • Kangstem Biotech
  • MEDIPOST
  • Mesoblast
  • NuVasive
  • Orthofix
  • Personalized Stem Cells
  • PHARMICELL
  • Pluristem Therapeutics
  • Regrow Biosciences
  • RTI Surgical
  • Smith & Nephew
  • Stempeutics Research
  • Under Pipeline Athersys
  • Takeda Pharmaceutical Company
  • ViaCyte

第9章 全球干细胞治疗市场，各地区，2019年～2030年(100万美元)

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲
简介目录
Product Code: BIOT2233

Global Stem Cell Therapy Market projected to be worth USD 700.19 million by 2030.

According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.

Impact of COVID-19 on the Stem Cell Therapy Market

COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Type, By Cell Source, By Therapeutic Application, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte

Driver: funding for stem cell research

Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.

Restraints:

Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.

Opportunity:

Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.

Global Stem Cell Therapy Market, By Type:

Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.

Global Stem Cell Therapy Market, By Cell Source:

Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.

Global Stem Cell Therapy Market, By Therapeutic Application:

Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.

Global Stem Cell Therapy Market, By Region:

North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Stem Cell Therapy Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Stem Cell Therapy Market, By Type, 2019-2030 (USD Million)

  • 6.1. Allogeneic Stem Cell Therapy
  • 6.2. Autologous Stem Cell Therapy

7. Global Stem Cell Therapy Market, By Cell Source, 2019-2030 (USD Million)

  • 7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
  • 7.2. Bone marrow-derived MSCs,
  • 7.3. Placental/umbilical cord-derived MSCs, and
  • 7.4. Other Cell Sources

8. Global Stem Cell Therapy Market, By Therapeutic Application, 2019-2030 (USD Million)

  • 8.1. Cardiovascular Diseases
  • 8.2. Inflammatory & Autoimmune Diseases
  • 8.3. Musculoskeletal Disorders
  • 8.4. Neurological Disorders,
  • 8.5. Other Therapeutic Applications
  • 8.6. Surgeries,
  • 8.7. Wounds & Injuries

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments

9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. AlloSource
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Anterogen
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. BioRestorative Therapies
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. BrainStorm Cell Therapeutics
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Cellular Biomedicine Group
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. CORESTEM
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Holostem Terapie Avanzate S.r.l
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hope Biosciences
    • 10.7.5. Company details
    • 10.7.6. Financial outlook
    • 10.7.7. Product summary
    • 10.7.8. Recent developments
  • 10.9. JCR Pharmaceuticals
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.10. Kangstem Biotech
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. MEDIPOST
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. Mesoblast
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. NuVasive
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Orthofix
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. Personalized Stem Cells
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. PHARMICELL
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. Pluristem Therapeutics
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. Regrow Biosciences
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. RTI Surgical
    • 10.18.5. Company details
    • 10.18.6. Financial outlook
    • 10.18.7. Product summary
    • 10.18.8. Recent developments
  • 10.20. Smith & Nephew
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Stempeutics Research
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Under Pipeline Athersys
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takeda Pharmaceutical Company
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. ViaCyte
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments